Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient‐reported outcomes substudy

TAILORx (Trial Assigning Individualized Options for Treatment) prospectively assessed fatigue and endocrine symptoms among women with early‐stage hormone receptor–positive breast cancer and a midrange risk of recurrence who were randomized to endocrine therapy (E) or chemotherapy followed by endocrine therapy (CT+E).

[1]  R. Gray,et al.  Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. , 2021, JAMA oncology.

[2]  A. Neugut,et al.  Patient Reported Outcomes and Long-Term Non-Adherence to Aromatase Inhibitors. , 2021, Journal of the National Cancer Institute.

[3]  L. Wagner.  Patient-Reported Outcomes Bridge an Important Gap in Identifying Risk for Early Endocrine Therapy Discontinuation. , 2021, Journal of the National Cancer Institute.

[4]  A. Papadaki,et al.  Chemotherapy Associated Ovarian Failure , 2020, Frontiers in Endocrinology.

[5]  J. Olson,et al.  Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. , 2020, JAMA oncology.

[6]  S. Michiels,et al.  Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Irwin,et al.  Fatigue After Breast Cancer Treatment: Biobehavioral Predictors of Fatigue Trajectories , 2018, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[8]  T. Whelan,et al.  Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03) , 2018, Breast Cancer Research and Treatment.

[9]  Oguzhan Alagoz,et al.  Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012 , 2018, JAMA.

[10]  H. Earl,et al.  aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  David Cella,et al.  How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. , 2011, Archives of physical medicine and rehabilitation.

[12]  Dawn L. Hershman,et al.  Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer , 2011, Breast Cancer Research and Treatment.

[13]  D. Patrick,et al.  Patient-reported outcomes to support medical product labeling claims: FDA perspective. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  C. Gotay,et al.  Assessment of Survivor Concerns (ASC): A newly proposed brief questionnaire , 2007, Health and quality of life outcomes.

[15]  J. Cuzick,et al.  Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer , 2006, Breast Cancer Research and Treatment.

[16]  Timothy L. Lash,et al.  Adherence to tamoxifen over the five-year course , 2006, Breast Cancer Research and Treatment.

[17]  Louise Atkins,et al.  Intentional and non-intentional non-adherence to medication amongst breast cancer patients. , 2005, European journal of cancer.

[18]  R. Hays,et al.  Clinical significance of patient-reported questionnaire data: another step toward consensus. , 2005, Journal of clinical epidemiology.

[19]  P. Jacobsen,et al.  Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. , 2007, Journal of pain and symptom management.